Under the terms of the agreement, Agilent will make an undisclosed settlement payment to Invitrogen. In addition, Agilent will discontinue sales of its RNase H minus RT products and Invitrogen will obtain a license from Agilent and pay an undisclosed royalty to sell its DNA polymerase blend products. All litigation will be dismissed.
The settlement resolves three patent infringement lawsuits between Invitrogen and Stratagene. Agilent acquired Stratagene in 2007.